Tango Therapeutics Inc (TNGX NASDAQ) stock market data APIs
$5.7478
-0.26(-4.5%)
as of July 8, 2025
Try our APIs with
free plan!
Tango Therapeutics Inc Financial Data Overview
Price chart is built with
Anychart
Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma. It is developing TNG260, a co-repressor of repressor element-1 silencing transcription inhibitor to reverse the immune evasion effect of serine-threonine kinase 11 loss-of-function mutations for treating lung cancer. The company was founded in 2017 and is headquartered in Boston, Massachusetts.
Prev. Close
5.7478
Open
5.4846
High
5.7727
Low
5.5332
52 wk Range
1.03-12.015
Market Cap
618 M
Shares Outstanding
108 M
Revenue
40 990 K
EPS
-0.36
Beta
1.244
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Tango Therapeutics Inc data using free add-ons & libraries
Get Tango Therapeutics Inc Fundamental Data
Tango Therapeutics Inc Fundamental data includes:
- Net Revenue: 40 990 K
- EBITDA: -143 374 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-06
- EPS/Forecast: -0.3459
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Tango Therapeutics Inc News
New
Tango Therapeutics' SWOT analysis: biotech stock's potential in precision cancer therapies
Tango Therapeutics, Inc. (NASDAQ:TNGX), a biotechnology company focused on discovering and delivering precision cancer therapies, has been garnering attention from investors and analysts alike. The co...
Tango Therapeutics doses first patient in cancer drug combo trial
BOSTON - Tango Therapeutics (NASDAQ:TNGX), whose stock has surged nearly 58% over the past six months according to InvestingPro data, has dosed the first patient in a Phase 1/2 trial testing its TNG46...
Tango Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of TNG462 plus Revolution Medicines’ Daraxonrasib or Zoldonrasib in Patients with RAS-Mutant MTAP-deleted Pancreatic or Lung Cancer
BOSTON, June 27, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering the next generation of precision cancer medicines, ...
Tango Therapeutics (TNGX) Moves 7.5% Higher: Will This Strength Last?
Tango Therapeutics, Inc. (TNGX) shares rallied 7.5% in the last trading session to close at $5.16. This move can be attributable to notable volume with a higher number of shares being traded than in a...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
